Format

Send to

Choose Destination
Radiother Oncol. 2015 Mar;114(3):351-6. doi: 10.1016/j.radonc.2015.02.014. Epub 2015 Mar 10.

A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer.

Author information

1
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Provincial Key Laboratory of Radiation Oncology, Jinan, China.
2
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Provincial Key Laboratory of Radiation Oncology, Jinan, China; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, China.
3
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Provincial Key Laboratory of Radiation Oncology, Jinan, China. Electronic address: xinglg@medmail.com.cn.

Abstract

BACKGROUND:

Acute radiation-induced esophagitis (ARIE) is one of main toxicities complicated by thoracic radiotherapy, influencing patients' quality of life and radiotherapy proceeding seriously. It is difficult to be cured rapidly so far. Our phase I trial preliminarily showed that EGCG may be a promising strategy in the treatment of ARIE.

MATERIALS AND METHODS:

We prospectively enrolled patients with stage III lung cancer from the Shandong Tumor Hospital & Institute in China from January 2013 to September 2014. All patients received concurrent or sequential chemo-radiotherapy, or radiotherapy only. EGCG was administrated once ARIE appeared. EGCG was given with the concentration of 440μmol/L during radiotherapy and additionally two weeks after radiotherapy. RTOG score, dysphagia and pain related to esophagitis were recorded every week.

RESULTS:

Thirty-seven patients with stage IIIA and IIIB lung cancer were enrolled in this trial. In comparison to the original, the RTOG score in the 1st, 2nd, 3rd, 4th, 5th week after EGCG prescription and the 1st, 2nd week after radiotherapy decreased significantly (P=0.002, 0.000, 0.000, 0.001, 0.102, 0.000, 0.000, respectively). The pain score of each week was significantly lower than the baseline (P=0.000, 0.000, 0.000, 0.000, 0.006, 0.000, 0.000, respectively).

CONCLUSION:

This trial confirmed that the oral administration of EGCG is an effective and safe method to deal with ARIE. A phase III randomized controlled trial is expected to further corroborate the consequence of EGCG in ARIE treatment.

KEYWORDS:

Acute radiation-induced esophagitis (ARIE); Epigallocatechin-3-gallate (EGCG); Phase II trial

PMID:
25769379
DOI:
10.1016/j.radonc.2015.02.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center